Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials

Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc.
announced today that voclosporin is positioned to enter a Phase 1
clinical trial as the drug utilized in the CINATRA(TM) Drug Coated
Coronary Stent system developed by the Company's partner, Atrium
Medical Corporation. Atrium has received approval from the Belgian
Competent Authority to commence the trial.

This First-in-Man trial is a prospective, multi-centre, single
blind, randomized, controlled clinical trial of the CINATRA(TM)
Voclosporin Coated Coronary Stent System as compared to the bare
metal CINATRA(TM) Coronary Stent System. The trial is expected to
involve up to 100 patients and will be conducted at seven clinical
trial sites in Belgium with Glenn Van Langenhove, MD, PhD of
Middelheim Hospital Antwerp as Principal Investigator. The primary
endpoint of the trial is to evaluate the safety and performance of
the CINATRA(TM) Voclosporin Coated Coronary Stent System and the
CINATRA(TM) Coronary Stent System in patients with de novo coronary
artery disease. The performance will be assessed by measuring the
Late Lumen Loss, in-stent and in-segment at six months post
procedure.

Trevor Carlton, Atrium's President, commented, "We are extremely
excited to be able to test our new CINATRA(TM) stent platform,
voclosporin and our proprietary O3FA coating technology that merges
the desirable safety benefits of a bare metal stent with the clinical
advantages of a drug eluting stent creating a new class of patient
treatment options. Interventional cardiologists and patients alike
have been waiting for a technology that delivers the effectiveness of
a new drug and coating platform that leaves a safe bare metal stent
in place after a short period of time in the body."

"Having voclosporin set to commence clinical trials in another
application is an exciting opportunity for the company," stated Dr.
Robert Foster, Isotechnika's Chairman & CEO.

About CINATRA(TM) Voclosporin Coated Coronary Stent System

The CINATRA(TM) Voclosporin Coated Coronary Stent System is
comprised of a cobalt chromium bare metal stent mounted on a delivery
balloon catheter. The stent and the balloon are coated with Atrium's
proprietary Omega-3 fatty acid coating technology utilizing
voclosporin for its anti-inflammatory properties.

About Isotechnika Inc.

Edmonton-based Isotechnika Inc. is an international
biopharmaceutical company focused on the discovery and development of
novel immunosuppressive therapeutics that are designed to offer
advantages over other currently available treatments. There is a
significant unmet medical need in the treatment of both solid organ
transplantation and autoimmune disease. It is estimated that the
market potential will exceed CAD$4 billion annually in sales for
calcineurin inhibitors such as voclosporin by 2010.

Voclosporin is a next generation calcineurin inhibitor, which
recently completed a Phase 2b North American trial for the prevention
of kidney rejection following transplantation. An extension to the
Phase 2b trial and a combined Phase 3 European/Canadian trial for the
treatment of moderate to severe psoriasis are ongoing. Our partner,
Lux Biosciences, is currently conducting three separate Phase 2/3
pivotal trials investigating voclosporin (referred to as LX211 by
Lux) for the treatment of uveitis.

Isotechnika Inc. is a publicly traded company on the Toronto
Stock Exchange under the symbol "ISA". More information on
Isotechnika can be found at http://www.isotechnika.com.

About Atrium

Atrium's vast expertise in medical device technologies for the
treatment of cardiovascular disease, hernia and adhesion prevention
has brought a number of breakthrough advances in several diversified
healthcare markets including interventional cardiology and
radiology, chest trauma care and thoracic drainage, vascular
surgery, and soft tissue repair. Maintaining a commitment to the
latest ISO13485 Quality Standards, state-of-the-art manufacturing
and automation, cell biology and biomaterial discovery programs,
Atrium continues to excel in those healthcare segments that require
more advanced surgical intervention for improvements in patient
outcome. For more information, call 800-370-7899 or visit
http://www.atriummed.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, events
or developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Forward-looking statements, including the Company's
belief as to the potential of its products, the Company's
expectations regarding the issuance of additional patents and the
Company's ability to protect its intellectual property, involve
known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, securing and maintaining corporate alliances, the need
for additional capital and the effect of capital market conditions
and other factors on capital availability, the ability to
economically manufacture its products, the potential of its
products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its
products, competition, the ability of the Company to defend its
patents from infringement by third parties, and the risk that the
Company's patents may be subsequently shown to be invalid or
infringe the patents of others. Additional risks and uncertainties
relating to the Company and its business can be found in the "Risk
Factors" section of the Company's Annual Information Form. These
factors should be considered carefully and readers are cautioned not
to place undue reliance on such forward-looking statements.

For further information:
Dr. Robert Foster
Chairman & CEO
Isotechnika Inc.,
Phone: +1-780-487-1600 Ext.272
Fax: +1-780-484-4105
Email: rfoster@isotechnika.com
Stephanie Gillis-Paulgaard
Director
Corporate Communications
Isotechnika Inc.
Phone: +1-780-487-1600 Ext. 243
Fax: +1-780-484-4105
E-mail:sgillis-paulgaard@isotechnika.com

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Robert Foster, Chairman & CEO,
Isotechnika Inc., Phone: +1-780-487-1600 Ext.272, Fax:
+1-780-484-4105, Email: rfoster@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-780-487-1600 Ext. 243, Fax: +1-780-484-4105,
E-mail:sgillis-paulgaard@isotechnika.com